Skip to main content
National Practice Guide · L3

China Drug Patent Linkage: Early Resolution, Generic Challenges & Originator Defence

Patent linkage connects generic/biosimilar marketing applications to listed patents so disputes surface before full market free-for-all. Originators use it to defend franchises; challengers use it to clear a path. Both sides need litigation calendars aligned with NMPA review clocks.

Updated13 Aug 2026
AudienceForeign businesses & individuals
Author China Law List Editorial · Reviewer Jinrong Zhou · Last reviewed · 3 min read · Editorial policy · AI content policy · Disclaimer · Not legal advice — confirm current rules with counsel and authorities

At a glance

Practice: typical process stages

Four high-level stages — details and local variations are in the guide below.

  1. FrameMap facts to PRC rules
  2. PlanOptions, risks & timeline
  3. ExecuteFilings, contracts, forums
  4. ReviewCompliance & next steps
City hubs

Local guides & lawyers

Drill into city × practice hubs where available, or open the city legal market guide.

General information only. Life sciences regulation in China spans NMPA product rules, PIPL/data security, human genetic resources, anti-corruption, volume-based procurement, IP, and clinical trial regimes. Facts, licences, and enforcement practice change. This is not legal advice and does not create an attorney–client relationship. Instruct qualified PRC counsel (and foreign counsel where FDA/EMA/CFIUS paths apply) before you recall product, transfer samples, answer a raid, or file a patent challenge.

Life sciences & healthcare legal cluster: Hub · Dawn raid · VBP · Hospital AR · Exclusive agency · HGR · Trial injury · CRO/CDMO · Device liability · Labeling · SaMD · Patent linkage · License · FDA WL · MDR/IVDR · Internet hospital · Trade secrets · Pharma ads · Device distribution · Sources · Checklist

Why in-house teams search this

  • Generic filings with non-infringement / invalidity-style declarations against listed patents.
  • Originator decisions: sue, seek administrative avenues, settle, or authorise.
  • Launch-at-risk calculus and preliminary measure strategy.
  • Coordination with global patent families and foreign litigations.

Process posture (orientation)

Expect a structured interplay among patent information registration, applicant declarations, notice to rights holders, and civil litigation and/or administrative adjudication routes under the linkage framework. Deadlines are unforgiving—build a watch service on your listed patents and competitive filings, not ad-hoc Google alerts.

Generic challenge themes

Challengers attack validity (including data sufficiency fights) or design around claims. Post-filed experimental data practice in invalidation can be decisive—align patent and regulatory data strategies early. FTO for the commercial process and formulation sits beside linkage litigation, not after it.

Originator defence themes

  • Portfolio hygiene: listable patents that actually block commercially relevant products.
  • Evidence packs for infringement (samples, process inference, expert experiments).
  • Settlement structures that survive anti-monopoly and tender optics.
  • Parallel trade-secret protection when reverse-engineering disputes appear.

PTE / exclusivity-adjacent timing

Patent term extension and regulatory exclusivity concepts affect how long a franchise is worth defending. Model dates explicitly; do not assume US PTE arithmetic applies unchanged. Tax and deal teams should see the same timeline as litigators when valuing License-out remaining term (licensing guide).

General patent litigation and trade-secret materials remain useful for evidence and damages methodology, but linkage is a specialised procedural track—use this page as the healthcare door, then deep-dive statutes with patent counsel.

Primary sources · Hub

FAQ · 高频检索问题

Chinese long-tail intents mapped to this guide (orientation only).

中国药品专利链接诉讼流程是什么?
Linkage connects listing, declarations, notices, and civil/administrative dispute routes to NMPA review clocks—build a watch service and response calendar.
仿制药 4 类声明如何应对?
Originators prepare infringement/validity evidence packs and decide sue/settle/authorise under deadline pressure; challengers align FTO with invalidation strategy.
专利期限补偿 / 数据独占如何影响策略?
Model franchise expiry explicitly; do not import US PTE arithmetic unchanged. Align with BD valuation on licence deals.

Need sector counsel?

Map your issue to a specialty desk: Life sciences & healthcare · Devices & IVD · Clinical & health data · Product liability · Industry hub.

Find counsel
Sources & trust

How to use this guide

This page is general information for orientation. It is not legal advice and does not create an attorney–client relationship. For methodology and AI-assisted drafting rules, see our Editorial Policy and AI Content Policy. Directory badge meaning is described in the Lawyer Verification Policy.

Prefer primary statutes, judicial interpretations, and official guidance when making decisions. Where this guide links to city hubs or lawyer listings, verify credentials and engagement terms directly with counsel. Full disclaimer · Request a consultation.

Directory

Verified Practice lawyers

China-based listings shown first. Browse lawyer profiles for practice, then request legal help.

Verified listingsconsultationChina-first directory sort

Browse practice directory →

Need counsel on practice?

Connect with listed lawyers to request legal help. No obligation.